PATIENT ASSISTANCE PROGRAMS

Size: px
Start display at page:

Download "PATIENT ASSISTANCE PROGRAMS"

Transcription

1 PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed for approved indications only. Completion of Class II Approval Form is necessary. In addition, where indicated, approval from Tumour Group Chair or delegate is required for reimbursement Reimbursement for approved indications only. Completion of the Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient The Patient Assistance Program chart is a general reference on the available programs offered by pharmaceutical manufacturers to help patients access specific drug therapies. Inclusion in the chart does not imply BC Cancer Agency endorsement of any drug therapy that is not approved on the BC Cancer Agency Benefit Drug List. Care has been taken to ensure accuracy of information; however it is not intended to replace specific information as provided by the manufacturer. Since program requirements are constantly evolving, it is advised that this chart not be used as a sole source of information. Home injection programs DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Buserelin (SUPREFACT ) Sanofi-Aventis Class I SUPREFACT Home Injection Program Medicum Patient Assistance Program Tel: Fax: Home delivery (weigh bills provided to pharmacies to ship buserelin and charge to the SUPREFACT Community Care and Home Injection Program) Home injection service (free of charge) 1/20

2 Goserelin (ZOLADEX ) Leuprolide (ELIGARD ) Leuprolide (LUPRON ) DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Degarelix (FIRMAGON ) Ferring Class I FIRMAGON Care Program Tel: Fax: Home delivery (weigh bills provided to pharmacies to ship degarelix and charge to the FIRMAGON Care Program) Home injection service (free of charge) for nonambulatory patients near major centers (caseby-case basis in remote regions) Astra-Zeneca Class I ZOLADEX Community Care and Home Injection Program Tel: Fax: Home delivery (weigh bills provided to pharmacies to ship goserelin and charge to the ZOLADEX Community Care and Home Injection Program) free of charge Sanofi-Aventis Class I ELIGARD Home Injection Program Tel: Fax: TAP Pharmaceuticals Class I Home delivery (weigh bills provided to pharmacies to ship leuprolide and charge to the ELIGARD Community Care and Home Injection Program) Home injection service (free of charge) LUPRON Comfort Program Tel: Fax: Help for patients to obtain third party coverage Financial assistance may be provided Home injection service (free of charge) 2/20

3 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Octreotide (SANDOSTATIN ) Novartis Pharmaceuticals Class I Access SANDOSTATIN LAR Tel: Fax: Help for patients to obtain third party coverage Financial assistance may be provided Home injection service (free of charge) 3/20

4 Supportive care medications DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Aprepitant (EMEND ) Merck PharmaCare Special Authority required. Dalteparin (FRAGMIN ) Darbepoetin (ARANESP ) Pfizer Amgen Funded by for approved indications for inpatient use only. Funded by for approved indications for inpatient use only. Merck Canada Patient Assistance Program Tel: Fax: Compassionate supply is available to patients without third party insurance coverage Once certain criteria are met (i.e. proof of low income) medication is delivered to prescriber s office or to a designated pharmacy to dispense and for patient pick up Fragmin SmartSample Program Tel: Once prescribed by the physician, the physician will: o Apply for PharmaCare Special Authority o Give the patient a SmartSample card The SmartSample card entitles the patient to a few free dalteparin pre-filled syringes from a community pharmacy for use while waiting for PharmaCare approval o o VICTORY Program Tel: Fax: treatment doses (5 free syringes) prophylactic doses (10 free syringes) Financial assistance is available to all patients who have third party insurance coverage but may need help with the Darbepoetin will be shipped by Victory program to a designated pharmacy Program to be initiated before patient goes to pharmacy Please fax form General Special Authority Request to PharmaCare Fax: PharmaCare Special Authority required. Please fax form Venous Thromboembolic Disease to PharmaCare Fax: /20

5 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Eltrombopag (REVOLADE ) GlaxoSmithKline inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income. Epoetin Alfa (EPREX ) Filgrastim (NEUPOGEN ) Janssen Amgen Funded by for approved indications for inpatient use only. SPECTRUM Support Program for Eprex Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the A compassionate supply is available to patients without third party insurance coverage, based on financial needs SPECTRUM program coordinates delivery with patients preferred pharmacy Initial self injection training with Nurse available in most regions. SPECTRUM program will coordinate nurse home visit with patient VICTORY Program Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the Victory Program will assist with the based on financial need and Fair PharmaCare deductible for each patient Compassionate supply will be shipped by Victory program to a designated pharmacy. Program to be initiated and PharmaCare approval established before patient goes to the pharmacy PharmaCare Special Authority required prior to program being initiated. Please fax form Filgrastim (GCSF) to PharmaCare Fax: /20

6 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Pegfilgrastim (NEULASTA ) Amgen VICTORY Program Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the Compassionate supply will be shipped by Victory program to a designated pharmacy If patient is prescribed NEULASTA and has no third party coverage, they will be offered NEUPOGEN Program to be initiated before patient goes to Valacyclovir (VALTREX ) GlaxoSmithKline pharmacy VALTREX Patient Assist Program Tel: Web: The VALTREX Patient Assist Program will cover up to the difference between the out of pocket amount of branded VALTREX (valacyclovir hydrochloride) versus the out of pocket amount a patient would have paid based on the average generic drug price. This amount will vary depending on each patient s coverage (i.e., public, private, none) in each province. Patients must first have their prescription filled at a community pharmacy and have the receipt when they call the program 6/20

7 Drugs with assistance/reimbursement programs and/or coordination of insurance coverage DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Abiraterone (ZYTIGA ) Afatinib (GIOTRIF ) Axitinib (INLYTA ) Janssen Boehringer Ingelheim Pfizer ZYTIGA Access Program (ZAP) Tel: Fax: Financial assistance is available to all patients with or without third party insurance No compassionate supply available Home delivery available through McKesson Pharmacy Home delivery of one blood pressure monitor per patient available HeadStart Patient Assistance Program Tel: Fax: Financial assistance is available to all patients with or without third party insurance Compassionate supply available Home delivery available through BioScript Pharmacy Program information can be found at: Pfizer Oncology Reimbursement Assistance Program - Inlyta Tel: Fax: Financial assistance is available to eligible patients with 7/20

8 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Bevacizumab (AVASTIN ) Bendamustine (TREANDA ) Bosutinib (BOSULIF ) Capecitabine (XELODA ) Roche Lundbeck Pfizer Roche Class II or based on indication Class II or based on indication Roche Patient Assistance Program Tel: Fax: Financial assistance is available to all patients with third party insurance coverage but may need help with the copay Infusion coordination provided if required TREANDA Patient Support Program Tel: Fax: No compassionate supply available Infusion coordination provided if required BOSULIF First Resource Program Tel: Fax: Financial assistance is available to patients with or without third party insurance Compassionate supply may be available Assistance offered until September 3, 2015 Roche Patient Assistance Program Tel: Fax: /20

9 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Ceritinib (ZYKADIA ) Crizotinib (XALKORI ) Dabrafenib (TAFINLAR ) Novartis Pfizer GlaxoSmithKline My Lungs Program Tel: Fax: Patients who were previously enrolled in the compassionate use program will get financial assistance with no limit. New patients will get 20% financial assistance. Home delivery available through McKesson Pharmacy XALKORI Reimbursement Support Program First Resource Program (Medicum) Tel: Fax: Crizotinib will only be provided to patients who have tested ALK-positive using a validated ALK assay at a laboratory with demonstrated proficiency in the specific technology Program does not coordinate or cover cost of ALK testing inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income. Patient must be BRAF-positive Program does not coordinate or cover cost of BRAF testing Home delivery available through BioScript Pharmacy 9/20

10 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Denosumab (XGEVA ) Doxorubicinpegylated liposomal (CAELYX ) Amgen VICTORY Program Tel: Fax: Janssen Class II Richard K. Plante, Director of Oncology, Janssen Tel: Mobile: rplante@its.jnj.com Enzalutamide (XTANDI ) Eribulin (HALAVEN ) Astellas Eisai or Myrna O Brodovich, Medical Information, Janssen Tel: medinfocanada@joica.jnj.com XTANDI Patient Assistance Program Tel: Fax: Financial assistance is available to all patients with or without third party insurance Home delivery available through McKesson Pharmacy Eisai Assistance Program Tel: Fax: No compassionate supply available Infusion coordination provided if required 10/20

11 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Erlotinib (TARCEVA ) Roche Class II or based on indication Roche Patient Assistance Program Tel: Fax: Financial assistance and RPAP services end March 31, 2015 Everolimus (AFINITOR ) Novartis Class II or based on indication InnoviCares - Tarceva benefit card: Program covers up to the difference in the drug ingredient cost between Tarceva and the respective generic alternatives Benefit card can be downloaded from AfiniTRAC Reimbursement Support Program Tel : Fax : /20

12 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Fulvestrant (FASLODEX ) Ibrutinib (IMBRUVICA ) Idelalisib (ZYDELIG ) AstraZeneca Janssen Gilead FasloCARE Program Tel: Fax: Financial assistance is available to patients with or without third party insurance Compassionate supply may be available InnoviCares - Faslodex benefit card: Program covers up to 20% of Faslodex prescription Benefit card can be downloaded from Faslodex Injection Support Program (FISP) Tel: Fax: Faslodex@innomar-strategies.com Offering injection services for patients with drug supply Imbruvica YOU&i TM Patient Support program Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the Compassionate drug access will end on 30 June 2015 Home delivery available through McKesson Pharmacy Gilead Oncology Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance Compassionate supply may be available 12/20

13 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Imatinib (GLEEVEC ) Interferon alpha (INTRON A ) Ipilimumab (YERVOY ) Lapatinib (TYKERB ) Novartis Class II GIST Alliance Tel: Fax: Merck Class I Merck Care TM Oncology Tel: Fax: Bristol-Myers Squibb GlaxoSmithKline Program covers up to 20% of drug cost YERVOY Access to Hope Program Tel: Fax: Enrolment criteria: not for off-label indications Financial assistance and compassionate supply available to all patients with or without third party insurance coverage on a case-by-case evaluation Prescribers must complete a certification program prior to prescribing the drug via inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income 13/20

14 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Lenalidomide (REVLIMID ) Letrozole (FEMARA ) Nilotinib (TASIGNA ) Pazopanib (VOTRIENT ) Celgene Novartis Pharmaceuticals Novartis GlaxoSmithKline Class I RevAid program Tel: Fax: Website: Compassionate supply may be available for non- funded indications Access FEMARA Tel: Fax: Compassionate supply of FEMARA available based on financial need GIST Alliance Tel: Fax: Program covers up to 20% of drug cost inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income 14/20

15 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Pembrolizumab (KEYTRUDA ) Pemetrexed (ALIMTA ) Merck Canada Lilly Class II or based on indication MERCK CARE Oncology Patient Assistance Program Tel: Fax: Enrolment criteria: Patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor as per proposed indication. Financial assistance available to patients with or without third party insurance coverage. Patients may be asked to based on household income Compassionate supply is available based on financial needs Patients previously enrolled in the compassionate use program will continue to receive supply for the duration of therapy Infusion coordination for new patients provided at private infusion clinics Bayshore HealthCare. For locations in BC, see: or keytruda@bayshore.ca ALIMTA Assistance with Reimbursement of Cost (ARC) Program Tel: Fax: Coordination of third party insurance coverage, including WorkSafeBC Based on financial need: o Financial assistance may be available to patients who have third party insurance coverage but may need help with the o Compassionate supply may be available 15/20

16 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Pertuzumab (PERJETA ) Pomalidomide (POMALYST ) Regorafenib (STIVARGA ) Roche Celgene Bayer Roche Patient Assistance Program (RPAP)- Perjeta Tel: Fax: Pomalyst Access Program Tel: Fax: Program opens for enrolment until March 31, 2015 Enrolment criteria: failed Bortezomib and Lenalidomide Financial assistance is available to all patients with or without third party insurance coverage Compassionate drug supply may be available ABC STIVARGA program Tel: Fax: Financial assistance available to all patients with or without third party insurance coverage Program covers up to 20% of drug cost 16/20

17 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Romidepsin (ISTODAX ) Rituximab (RITUXAN ) Romiplostim (NPLATE ) Celgene Roche Amgen Class II or based on indication ISTODAX Access Program Tel: Fax: Program opens for enrolment until March 31, 2015 Compassionate supply available to patients enrolled prior to March 31, 2014 Enrolment criteria: relapsed/refractory Peripheral T-Cell Lymphoma (PTCL) not eligible for stem cell transplant; failed at least one prior systemic therapy Financial assistance available to all patients with or without third party insurance coverage No infusion cost assistance Roche Patient Assistance Program Tel: Fax: Infusion coordination provided if required enable Support Program Tel: Fax: No compassionate assistance available 17/20

18 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Ruxolitinib (JAKAVI ) Sorafenib (NEXAVAR ) Temozolomide (TEMODAL ) Thalidomide (THALOMID ) Tocilizumab (ACTEMRA ) Novartis Bayer Novartis Alliance Program- MPN Alliance Tel : Fax : Merck Class II Merck Care TM Oncology Tel: Fax: Celgene Roche Assistance Bayer Canada (ABC) NEXAVAR Program Tel: Fax: RevAid program Tel: Fax: Website: Compassionate supply may be available for non- funded indications JointEffort program Tel: Fax: /20

19 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Trametinib (Mekinist ) Trastuzumab (HERCEPTIN ) Trastuzumab Emtansine (KADCYLA ) GlaxoSmithKline Roche Roche Class II or based on indication inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to based on household income Patient must be BRAF-positive Program does not coordinate or cover cost of BRAF testing Home delivery available through BioScript Pharmacy Roche Patient Assistance Program Tel: Fax: Infusion coordination provided, if required Roche Patient Assistance Program (RPAP)- Kadcyla Tel: Fax: Infusion coordination provided, if required 19/20

20 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE Vandetanib (CAPRELSA ) Vemurafenib (ZELBORAF ) Vismodegib (ERIVEDGE ) AstraZeneca Roche Roche CAPRELSA Distribution Program Tel: Website: Prescribing physicians and pharmacists need to complete a certification process and register with the program in order to enrol patients, prescribe and dispense vandetanib (CAPRELSA ). No compassionate supply of vandetanib offered by program Reimbursement guidance for patients with third party insurance coverage offered by Shoppers Drug Mart Specialty Health Network. Tel: See: Drugs with Special Ordering Procedures (SAP chart) Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to all patients with or without third party insurance Roche Patient Assistance Program/ERIVEDGE Pregnancy Prevention Program (RPAP/EPPP) Tel: Fax: Drug can only be dispensed to patients who are registered and meet all conditions of the EPPP. For more information contact EPPP at /20

NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT

NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT Please complete the Fax Cover Sheet and Service Request Form, and fax all pages to the number specified below. Dear Health Care Professional: The Novartis

More information

ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces

ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces Executive Summary November 18, 2015 In 2014, the American Cancer Society Cancer Action Network (ACS CAN)

More information

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room Guide The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians

More information

PATIENT APPLICATION FORM INSTRUCTIONS

PATIENT APPLICATION FORM INSTRUCTIONS INSTRUCTIONS The Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines at no cost. To apply online, access program information

More information

THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST. Date Request Received: 03 August 2015 FOI Ref: 947

THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST. Date Request Received: 03 August 2015 FOI Ref: 947 FREEDOM OF INFORMATION ACT 2000 THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST Date Request Received: 03 August 2015 FOI Ref: 947 Requested Information For the Royal Cornwall Hospitals

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

National Cancer Drugs Fund List (Updated 13 February 2014)

National Cancer Drugs Fund List (Updated 13 February 2014) National Cancer Drugs Fund List (Updated 13 February 2014) DRUG Abiraterone Aflibercept Axitinib Bendamustine NCDF APPROVED CRITERIA The treatment of metastatic castration resistant prostate cancer where

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Novel Opportunities for Engagement Utilizing in House Pharmacy Services

Novel Opportunities for Engagement Utilizing in House Pharmacy Services Novel Opportunities for Engagement Utilizing in House Pharmacy Services Ray Bailey, BSPharm RPh Director of Pharmacy, FCS Rx to Go Pharmacy rbailey@flcancer.com Angel Aslo, Pharm.D. Director of Pharmacy,

More information

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:

More information

NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT

NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT Please complete the Fax Cover Sheet and Service Request Form, and fax all pages to the number specified below. Dear Health Care Professional: The Novartis

More information

Patient Assistance PROGRAM PRIMER

Patient Assistance PROGRAM PRIMER Patient Assistance PROGRAM PRIMER The private benefits plan sponsor s guide to the patient assistance program Your guide to pharmaceutical manufacturers patient assistance programs for eligible plan members

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 March 2015 Welcome to the first COMPARE report. This report provides information

More information

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05- Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment

More information

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments

More information

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that

More information

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market

More information

Issues of Access to Cancer Drugs in Canada. A Report for the Canadian Cancer Action Network

Issues of Access to Cancer Drugs in Canada. A Report for the Canadian Cancer Action Network Issues of Access to Cancer Drugs in Canada A Report for the Updated April 2008 i Table of Contents Executive Summary iv Part 1 How Are Cancer Drugs Approved in Canada? Introduction 2 Section 1 National

More information

Effective Date: 6/3/14

Effective Date: 6/3/14 North Shore-Long Island Jewish Health System, Inc. Long Island Jewish Medical Center PATIENT CARE SERVICES POLICY TITLE: ORDERING, ADMINISTRATION AND DISPOSAL OF ORAL CHEMOTHERAPEUTIC AGENTS Prepared by:

More information

targeted therapy a guide for the patient

targeted therapy a guide for the patient targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment

KOL Insight: Non-small cell lung cancer Game changing immunotherapies to revolutionise treatment March 2014 KOL Insight: Non-small cell lung cancer A FirstWord Therapy Trends Report KOL Insight: Lung Cancer Published March 2014 Copyright 2014 Doctor s Guide Publishing Limited All rights reserved.

More information

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

Comprehensive pharmacist-managed oral chemotherapy monitoring, education, and adherence program

Comprehensive pharmacist-managed oral chemotherapy monitoring, education, and adherence program Comprehensive pharmacist-managed oral chemotherapy monitoring, education, and adherence program Becky Fahrenbruch, Pharm D, BCOP Fairview Maple Grove Medical Center Oncology Infusion Pharmacy Maple Grove,

More information

April 2014 Medicine use and shifting costs of healthcare

April 2014 Medicine use and shifting costs of healthcare April 2014 Medicine use and shifting costs of healthcare A review of the use of medicines in the United States in 2013 Introduction In 2013, per capita use and cost of medicines increased 0.9% and 1.0%

More information

Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009

Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009 Specialty Pharmacy: Understanding the Market and Solution Presented by Chris Brown November 2009 Your Goals What What is a Specialty is a specialty Medication? medication? Specialty drugs are injectable,

More information

Bristol-Myers Squibb Access Support Program. What Medications does the BMS Access Support Program help with? Program Registration Steps

Bristol-Myers Squibb Access Support Program. What Medications does the BMS Access Support Program help with? Program Registration Steps Oncology Reimbursement Support Phone: 1-800-861-0048 Fax: 1-888-776-2370 Bristol-Myers Squibb Access Support Program The Bristol-Myers Squibb Access Support Program is designed to help patients with reimbursement

More information

31/10/2013. Dr Martin Eatock Consultant Medical Oncologist Chair NICaN D+T Committee. Year

31/10/2013. Dr Martin Eatock Consultant Medical Oncologist Chair NICaN D+T Committee. Year 20 Oncologists & Hematologists surveyed across Northern Ireland HSC trusts 18 Consultants, 2 SpRs 10 Oncologists, 10 Hematologists 4 Cancer service centers All with some/significant involvement in applying

More information

Northwest Georgia Oncology Centers, P.C.

Northwest Georgia Oncology Centers, P.C. Northwest Georgia Oncology Centers, P.C. High Deductibles and Out of Pocket HSA/HRA Plans (No up front collection) Medicare Advantage Plans Healthcare Exchange Plans Medicare only Cobra plans/high premiums

More information

The Cancer Market Outlook to 2016. Competitive landscape, market size, pipeline analysis, and growth opportunities

The Cancer Market Outlook to 2016. Competitive landscape, market size, pipeline analysis, and growth opportunities The Cancer Market Outlook to 2016 Competitive landscape, market size, pipeline analysis, and growth opportunities Reference Code: BI00042-009 Publication Date: June 2011 1 About Business Insights Business

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

May 2014 Innovation in cancer care and implications for health systems

May 2014 Innovation in cancer care and implications for health systems May 2014 Innovation in cancer care and implications for health systems Global oncology trend report Introduction Cancer remains a top priority for health systems around the world as incidence levels rise,

More information

What s New With HER2?

What s New With HER2? What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing

More information

Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer

Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer www.nshealth.ca Hormone Therapy for Prostate Cancer What is the prostate? The prostate is one of the male sex glands. It makes seminal fluid

More information

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012 The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered

More information

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Prostate Cancer: Key Metrics in the 9MM, 2013 2023 2013 Epidemiology

More information

FREE ANSWER ONLINE FOR INSTANT RESULTS AT WWW.CANADIANHEALTHCARENETWORK.CA SEPTEMBER 2015. by Sanna Pellatt, BSc(Pharm) Learning objectives

FREE ANSWER ONLINE FOR INSTANT RESULTS AT WWW.CANADIANHEALTHCARENETWORK.CA SEPTEMBER 2015. by Sanna Pellatt, BSc(Pharm) Learning objectives FONT: HELVETICA NEUE 75 BOLD (MODIFIED) CYAN 50,YELLOW 100 MAGENTA 100 CYAN 100 Continuing Education THE NATIONAL CONTINUING EDUCATION PROGRAM FOR PHARMACY TECHNICIANS 1.25 CEUs FREE ANSWER ONLINE FOR

More information

Outpatient Prescription Drug Benefit

Outpatient Prescription Drug Benefit Outpatient Prescription Drug Benefit GENERAL INFORMATION This supplemental Evidence of Coverage and Disclosure Form is provided in addition to your Member Handbook and Health Plan Benefits and Coverage

More information

National Cancer Drugs Fund List Ver5.1

National Cancer Drugs Fund List Ver5.1 National Cancer Drugs Fund List Ver5.1 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans. & Corp. Ops. Commissioning Strategy Finance

More information

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies.

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies. PHARMANET AND PHARMACARE DATA DICTIONARY Date Range: September 1, 1995 to present date, data is provided by calendar year Data Source: BC Ministry of Health Description The PharmaNet system is an online,

More information

New Oncology Drug Approvals and FDA Review in the United States

New Oncology Drug Approvals and FDA Review in the United States By Samantha A. Roberts, Jeff D. Allen, and Ellen V. Sigal Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe doi: 10.1377/hlthaff.2011.0231

More information

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare

More information

Specialty Drug Management Solutions You Haven t Heard Before

Specialty Drug Management Solutions You Haven t Heard Before Specialty Drug Management Solutions You Haven t Heard Before Sarah Martin, ASA, MAAA, CEBS Vice President, Senior Pharmacy Consultant Lockton Kansas City, Missouri The opinions expressed in this presentation

More information

Information and Insight into Breast Cancer in China. White Paper. by Neesha Suvarna, PhD Consultant, Kantar Health November 2011

Information and Insight into Breast Cancer in China. White Paper. by Neesha Suvarna, PhD Consultant, Kantar Health November 2011 White Paper Catalysts driving successful decisions in life sciences. Information and Insight into Breast Cancer in China by Neesha Suvarna, PhD Consultant, Kantar Health November 2011 www.kantarhealth.com

More information

Great-West s Drug Prior Authorization

Great-West s Drug Prior Authorization Great-West s Drug Prior Authorization Great-West Life s prior authorization process is designed to provide an effective approach to managing claims for specific prescription drugs. Approval for coverage

More information

Specialty Drug Program RX Benefit Member Guide

Specialty Drug Program RX Benefit Member Guide Specialty Drug Program RX Benefit Member Guide bcbsm.com Enrollment Form for Walgreens Specialty Pharmacy, LLC. How to place your initial order with Walgreens Specialty Pharmacy: 1) Print and complete

More information

Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON

Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON Disclosures Speaker honorarium from Bayer (rivaroxaban; Xarelto) and

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Manufacturer of drug substance

Manufacturer of drug substance Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin

More information

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.

More information

Patient Assistance Program Primer

Patient Assistance Program Primer Patient Assistance Program Primer Suzanne Lepage Private Health Plan Strategist Suzanne Lepage Consulting Inc. Kitchener, Ontario The opinions expressed in this presentation are those of the speaker. The

More information

REVISING SPECIALTY TIERS

REVISING SPECIALTY TIERS WHITE PAPER REVISING SPECIALTY TIERS PROTECTING MEDICARE PART D BENEFICIARIES FROM BURDENSOME COST SHIFTING Gary G., Michigan Gary thought he had his financial assistance grant set up to cover his out-of-pocket

More information

BreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME

BreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME BreastCancerTrials.org History Form: Metastatic Breast Cancer This form is for patients with metastatic breast cancer who were: Were recently diagnosed with metastatic breast cancer (cancer that has spread

More information

Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided

Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided FOR MORE ABOUT OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT THE OHC RESEARCH DEPARTMENT AT 1.800.710.4678. Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Eribulin

More information

Nova Scotia Pharmacare Programs

Nova Scotia Pharmacare Programs Nova Scotia Pharmacare Programs The Nova Scotia Family Pharmacare Program Effective December 2012 The information in this booklet is subject to change and does not replace the Health Services and Insurance

More information

Insurance and Reimbursement Resources for MDS Patients

Insurance and Reimbursement Resources for MDS Patients Insurance and Reimbursement Resources for MDS Patients A Guide to Assistance Programs in the United States Third Edition the myelodysplastic syndromes foundation, inc. Published by The Myelodysplastic

More information

The Ins and Outs of Medicare Open Enrollment

The Ins and Outs of Medicare Open Enrollment The Ins and Outs of Medicare Open Enrollment Christina Bach, MSW, MBE, LCSW, OSW- C Educational Content Specialist and Psychosocial Content Editor, OncoLink Quick Review of Terminology Premium- the monthly

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

New Oral Chemotherapeutic Agents: Part B vs. Part D Implications

New Oral Chemotherapeutic Agents: Part B vs. Part D Implications New Oral Chemotherapeutic Agents: Part B vs. Part D Implications Steven L. D Amato RPh, BCOP Maine Center for Cancer Medicine Scarborough, ME Introduction The majority of oncology care (>80%) occurs in

More information

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions Q1. What members are impacted by the UnitedHealthcare Injectable Chemotherapy PA Program? A. Beginning

More information

Saving Money on Prescription Drugs

Saving Money on Prescription Drugs Reference Guide to Saving Money on Prescriptions Revised: July 11, 2006 Prescription medications can be a heavy financial burden for individuals and families. Many people feel limited to receiving assistance

More information

Welcome to. Prompt Fulfillment and Delivery 1-844-CUBIST-CARES (1-844-282-4782)

Welcome to. Prompt Fulfillment and Delivery 1-844-CUBIST-CARES (1-844-282-4782) Welcome to When you prescribe SIVEXTRO (tedizolid phosphate) to your patients, our goal is to ensure they have access. That is why AccessSIVEXTRO is committed to helping eligible patients so they can receive

More information

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee PICA PRESCRIPTION DRUG PROGRAM Self-Injectable Medications Chemotherapy Medications Questions & Answers Last

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:

More information

Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology. CME Information

Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology. CME Information Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology CME Information TARGET AUDIENCE This activity is intended for medical oncologists, hematologists,

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > June 2014 Specialty Pipeline Update New Drug Information Eloctate (recombinant factor VIII Fc fusion protein): Biogen received FDA approval for their hemophilia A for

More information

Pharmaceutical Risk Sharing Agreements C. Bernie Good MD MPH Department of Veterans Affairs June 2014

Pharmaceutical Risk Sharing Agreements C. Bernie Good MD MPH Department of Veterans Affairs June 2014 Pharmaceutical Risk Sharing Agreements C. Bernie Good MD MPH Department of Veterans Affairs June 2014 Objectives Describe concept of Risk-Share Agreements Describe types of agreements Identify specific

More information

8. Malignant disease and immunosuppression

8. Malignant disease and immunosuppression 1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of

More information

Your Retiree Health Care Travel Guide

Your Retiree Health Care Travel Guide SPECIAL EDITION for Individuals Not Yet Eligible for Medicare Your Retiree Health Care Travel Guide 2010 Enrollment for BorgWarner Pre-Medicare Health Care Coverage Welcome to 2010 Pre-Medicare enrollment!

More information

Treatment for Lung Cancer: Drug Therapy

Treatment for Lung Cancer: Drug Therapy Treatment for Lung Cancer: Drug Therapy Living in the Molecular Age: Advances Drug Therapy of Lung Cancer John C. Morris, M.D. Division of Hematology-Oncology November 1, 2014 Non-small cell lung cancer:

More information

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 July 2014 Review of the List of High-Cost Medicines Used by the

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

NEW DRUG APPROVALS IN ICH COUNTRIES 2004 2013 FOCUS ON 2013

NEW DRUG APPROVALS IN ICH COUNTRIES 2004 2013 FOCUS ON 2013 24 24 24 Approval time (days) Approval time (years) NEW DRUG APPROVALS IN ICH COUNTRIES 24 FOCUS ON Median 25 th and 75 th percentile 12 1 8 6 NASs approval time by approval year 24- Median; 25 th and

More information

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM ABBVIE EMPLOYEES WANT TO KNOW What s New in 2015? AbbVie is making changes in its pharmacy benefit program to ensure our medical

More information

FOURTH EDITION. Metastatic Breast Cancer

FOURTH EDITION. Metastatic Breast Cancer FOURTH EDITION Metastatic Breast Cancer Dedicated to all the people with metastatic breast cancer who shared their stories, experiences and wisdom to make this guide possible. Table of Contents CHAPTER

More information

Medicare Drug Coverage Under Part A, Part B, and Part D

Medicare Drug Coverage Under Part A, Part B, and Part D Medicare Drug Coverage Under Part A, Part B, and Part D Medicare Part A and Part B generally do not cover outpatient prescription drugs, most of which are now covered under Part D. This document and the

More information

Prescription Drug Benefit Description

Prescription Drug Benefit Description Prescription Drug Benefit Description Herein called Description Prescription Drug Program For State of Kansas Employees Health Plan This booklet describes the Prescription Drug benefits available through

More information

Approval rating: how do the EMA and FDA compare?

Approval rating: how do the EMA and FDA compare? Approval rating: how do the EMA and FDA compare? MARC BEISHON When new cancer therapies regularly become available more than half a year earlier in the US than in Europe, or get regulatory approval on

More information

HIGHLY SPECIALISED DRUGS PROGRAM AND HERCEPTIN PROGRAM. Western Australia Administrative Guidelines

HIGHLY SPECIALISED DRUGS PROGRAM AND HERCEPTIN PROGRAM. Western Australia Administrative Guidelines HIGHLY SPECIALISED DRUGS PROGRAM AND HERCEPTIN PROGRAM Western Australia Administrative Guidelines Pharmaceutical Services Branch Health Protection Group Table of Contents BACKGROUND...1 Overview...1 AHMAC

More information

Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs. Sandra Anderson August 2015

Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs. Sandra Anderson August 2015 Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs Sandra Anderson August 2015 Why Orphan Drugs are Different Difficult to diagnose Population size Unique patient and caregiver

More information

Towards a New Model of Delivery of Care

Towards a New Model of Delivery of Care Towards a New Model of Delivery of Care What can we do Different to Provide Better Delivery of Care? Algis Jovaisas, MD,FRCPC Division of Rheumatology University of Ottawa Current Modelsurrent Private

More information

Treating Recurrent Metastatic Breast Cancer

Treating Recurrent Metastatic Breast Cancer BREAST CANCER Treating Recurrent Metastatic Breast Cancer Presented by Julie Gralow, MD Fred Hutchinson Cancer Research Center Generosa Grana, MD UMDNJ/Robert Wood Johnson School of Medicine Patricia Spicer,

More information

PRESCRIPTION DRUG PLAN

PRESCRIPTION DRUG PLAN PRESCRIPTION DRUG PLAN The Plan Administrator will pay a portion of the cost of covered prescriptions. Maximum benefits are paid when prescriptions are filled through the CVS Caremark network pharmacies.

More information

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS 1. COMPANY DESCRIPTION Biocad is a Russian full cycle biotechnological company. It deals with development, manufacture and promotion of original

More information

ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers. May 1, 2012

ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers. May 1, 2012 ICORE Healthcare: Injectable Drug Utilization Management Program Overview for EmblemHealth Providers May 1, 2012 Agenda Topics for Today 1. Program Summary Specialty Injectable Drugs in scope EmblemHealth

More information

Specialty Drug Care: Case management services in Quebec

Specialty Drug Care: Case management services in Quebec Specialty Drug Care: Case management services in Quebec QUEBEC SUPPORTING HEALTHIER OUTCOMES Your health benefit plan is designed to provide you and your family with financial protection for a variety

More information

Cancercare Connect Booklet Series. Renal Cell Cancer. www.cancercare.org

Cancercare Connect Booklet Series. Renal Cell Cancer. www.cancercare.org Cancercare Connect Booklet Series Treatment Update Renal Cell Cancer www.cancercare.org Treatment Update Renal Cell Cancer Table of Contents The CancerCare Connect Booklet Series offers up-to-date, easy-to-read

More information

New Mexico Drug Donation Guide

New Mexico Drug Donation Guide New Mexico Drug Donation Guide 16.19.34.2 SCOPE: This section applies to licensed clinics and participating practitioners located within the state of New Mexico who provide for the donation and redistribution

More information

RMIP Prescription Plan FAQ's

RMIP Prescription Plan FAQ's RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on

More information

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute

More information

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists

More information